Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0011832936
Fri, 28.05.2021
Cosmo Pharmaceuticals N.V.
Dublin, Ireland - 28 May 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced that its shareholders approved all agenda items at today's virtual annual general meeting of shareholders.
7.227.632 ordinary shares in the capital of Cosmo were represented at this virtual annual general meeting of shareholders constituting 50.29% of [ … ]
Mon, 10.05.2021
Cosmo Pharmaceuticals N.V.
* retirement of Dr. Hans Christoph Tanner as non-executive director
* proposal for the appointment of Mr. David Maris as new non-executive board member
Dublin, Ireland - 10 May 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced the resignation, due to his retirement, of Dr. Hans Christoph Tanner as a non-executive board [ … ]
Mon, 19.04.2021
Cosmo Pharmaceuticals N.V.
Dublin, Ireland - 19 April 2021: Shares of Cosmo Pharmaceuticals NV ('Cosmo') (SIX: COPN), which have traded on the Swiss Stock Exchange since 2007, will now also trade on XETRA in Frankfurt, Germany. Trading will commence today, Monday, at 9:00am CEST under tickersymbol C43. COSMO PHARMACEUT. EO-,26 ISIN: NL0011832936 | WKN: A2AJ68 | Ric: C43 | Ty [ … ]
Mon, 12.04.2021
Cosmo Pharmaceuticals N.V.
Dublin, Ireland - 12 April 2021: Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius(TM) intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy.
The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research and investments focused to [ … ]